Skip to Main Content

Paper Details

Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
JAMA
202
2017
patient, psychiatric disease
Author NameAffiliation
Nicholas S DowningBrigham and Women's Hospital
Nilay D ShahDivision of Health Care Policy and Research and Kern Center for the Science of Health Care Delivery, Mayo Clinic
Harlan M KrumholzYale School of Medicine, Connecticut8The Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Public Health, Connecticut10Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
Harlan M KrumholzYale School of Medicine, Connecticut8The Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Public Health, Connecticut10Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
Joseph S RossYale School of Medicine, Connecticut8The Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Public Health, Connecticut10Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
  • 1 - 5

Datasets